Indian biopharma firm Biocon signs exclusive licensing and supply deal with South Korea's Handok Pharmaceuticals for synthetic Liraglutide, a chronic weight management drug.
Biocon Ltd, an Indian biopharma firm, signs an exclusive licensing and supply deal with South Korea's Handok Pharmaceuticals for synthetic Liraglutide, a drug used in chronic weight management. Biocon handles development, manufacturing, and supply, while Handok obtains regulatory approval and commercialises the drug in South Korea. The total addressable market for Liraglutide in South Korea is around $47 million.
May 24, 2024
3 Articles